Cephalon News

Biotech drugmaker Cephalon spent more than $512,000 lobbying the federal government in the first quarter, according to a government disclosure form. via International Business Times

Comment?

Shares of the following companies were among that made notable moves in the U.S. stock market Wednesday. via MarketWatch

Comment?

Cephalon, Inc. today announced plans to host an investor conference call at 5:30 p.m. EDT on May 6, 2008 to discuss the U.S. Food and Drug Administration advisory committee panel meeting held that day. via Med Ad News

Comment?

“We are disappointed with the recommendation of the Advisory Committee”

Cephalon, Inc. announced today that a Joint Advisory Committee to the U.S. Food and Drug Administration voted not to recommend approval of an expanded label for FENTORA [C-II] for the management of breakthrough ... via BioSpace

Comment?

Shares of Cisco Systems Inc. may see heavy trading Wednesday after the networking equipment maker posted a larger-than-expected profit in its fiscal third quarter. via Forbes

Comment?

“In my mind it is very scary to release such a large amount of powerful opiate into the American population.”

Medical experts on Tuesday voted against allowing a powerful painkiller made by Cephalon Inc. via BusinessWeek

Comment?

Sun Microsystems Inc. shares were hammered late Thursday after the company issued weak quarterly results and announced layoffs, and shares of Wynn Resorts Ltd. via MarketWatch

Comment?

“We remain cautious regarding the outcome of the panel and the product's potential in the broader non-cancer population”

By Susan Heavey

WASHINGTON (Reuters) - Allowing Cephalon Inc to market its Fentora pain drug more widely for patients without cancer could have "devastating effects," a U.S. Food and Drug Administration official said in documents released on Friday.

The company is seeking the FDA's approval to promote Fentora, or fentanyl, for sudden pain in non-cancer patients who have developed a tolerance to opioids. The drug is already approved in the United States for pain flare-ups in cancer patients. Read more

Comment?

Thomson Reuters Corp., a newly combined provider of business and legal information, forecast revenue growth between 6 percent and 8 percent for the year Thursday, despite turmoil in the U.S. financial sector. via Boston Globe

Comment?

Ballard Spahr Andrews & Ingersoll partner and former Pennsylvania Attorney General Jerry Pappert will become executive vice president and general counsel of biotechnology company Cephalon Inc. via Philadelphia Business Journal

Comment?